New Alzheimer’s Drugs (October 2024)
On July 2, 2024, the US Food and Drug Administration (FDA) approved donanemab-azbt, known by the brand name Kisunla, as a treatment for early-stage Alzheimer’s disease. This was exciting news for Alzheimer’s patients and a significant victory for researchers, given…